Navigation Links
Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
Date:11/6/2007

iotensin II, which was dose-dependent and long-lived but reversible with a half-life of about 4 months. Also efficacy was dose-dependent and a significant reduction of the mean ambulatory day-time blood pressure was observed in the group who received the 300 mg dose of the vaccine. Systolic blood pressure (SBP) was reduced by 5.6 mmHg and diastolic blood pressure (DBP) by 2.8 mmHg from baseline.

Furthermore, strong efficacy of the vaccine was observed in the early morning hours, a critical time period when serious cardiovascular events occur frequently. The early morning rise of blood pressure starting at 5 am was significantly reduced by the vaccine, leading at 8 am to a blood pressure difference from baseline of (SBP / DBP) - 25 / - 13 mmHg compared to placebo.

Prof. Juerg Nussberger comments: "Despite the fact that effective drugs are available to treat hypertension, only about one out of four hypertensive patients has the blood pressure successfully controlled. Once people are aware of the often symptomless hypertension, they have to take their medications daily, and many are apparently unable or unwilling to take pills every day for the rest of their lives. The major remaining medical need in this important therapeutic area is thus improved patient compliance. If we could support or substitute the oral therapy with a vaccine that would need to be given just every few months, I think we could achieve a better control of high blood pressure."

Prof. Nussberger adds: "A particularly interesting finding of this study is the excellent control of the blood pressure in the early morning hours achieved by the vaccine. This is a crucial time period when serious events like myocardial infarction and stroke are more likely to occur than during other times of the day. Since currently available drugs often have too short half-lives to affect the rise in early morning blood pressure, this could become a major advantage of the novel vaccine approach. I am loo
'/>"/>

SOURCE Cytos Biotechnology AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... ... manufacturing of surgical instruments in Orthopedics, announced today the acquisition of Turner ... world's largest provider of surgical instruments to the Spine Industry. The acquisition of ...
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... , SAN MATEO, Calif., Aug. 25 ... focused on developing and commercializing novel pain management therapies, today announced ... as a director and Audit Committee chairman, effective August 20, 2009. ... a company focused on exploiting a novel, Nobel Prize winning method ...
... Aug. 25 Repligen Corporation (Nasdaq: RGEN ... been elected to its Board of Directors. Dr. ... biotechnology industries with expertise in transforming development stage companies ... Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., ...
... , , SYDNEY, Aug. 25 ... global meltdown. By 2020 the government envisages this sector will employ up to ... Malaysia ,s GDP. , , (Logo: ... impact on the Malaysian economy has highlighted the need for Malaysia to focus ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors 2Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors 3Malaysian Biotechnology Sector 2Malaysian Biotechnology Sector 3Malaysian Biotechnology Sector 4
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/24/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Sharp has selected its industry-leading Natural ... its latest flagship smartphone device, the AQUOS ZETA ... shipments of its fingerprint ID sensor technology, this ... and leadership in the biometrics market through its ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... comprehensive look at market competition between wild and farmed ... issues surrounding farmed and wild salmon. , The ... released by TRAFFIC, the wildlife trade monitoring network of ... two important trends that have remade the salmon industry ...
... stem cells derived from muscle have a greater ability to ... study at Children’s Hospital of Pittsburgh of UPMC. , The ... of the Journal of Cell Biology, is the first ever ... cells based on sex. , This finding could have ...
... edition of the Proceedings of the National Academy of Sciences ... provides new evidence that Nod1, a member of the Nod-like ... which also activates Resistance (R) proteins in plants; R proteins ... similarities between the Nod1 protein, which plays a pivotal role ...
Cached Biology News:New report: Explosive growth changes salmon industry 2The sturdier sex? -- Study by Pittsburgh scientists finds female stem cells work better 2Scripps research study shows humans and plants share common regulatory pathway 2Scripps research study shows humans and plants share common regulatory pathway 3
... White to off-white solid. Increases the expression of ... Soluble in H 2 O. Unstable in ... RTECS EK7713840, CAS 3211-76-5, M.W. 196.1. References: ... L., and Junod, A.F. 1995. Biochem. J. ...
... antifade reagent is used to ... standard fluorescence microscopy. The unique ... a wide variety of fixed ... fluorescein, rhodamine, sulforhodamine 101, coumarin, ...
...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: